PAMIDRONATE DISODIUM

Post-LOE

pamidronate disodium

Fresenius Kabi

ANDAINJECTIONINJECTABLE

Approved

May 2002

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PAMIDRONATE DISODIUM (pamidronate disodium) by Fresenius Kabi is clinical pharmacology the principal pharmacologic action of pamidronate disodium is inhibition of bone resorption. Approved for moderate, severe hypercalcemia associated with malignancy, with and 3 more indications. First approved in 2002.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY The principal pharmacologic action of pamidronate disodium is inhibition of bone resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Pamidronate disodium adsorbs to calcium…

Worked on PAMIDRONATE DISODIUM at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

PAMIDRONATE DISODIUM

Mechanism of Action

Indications (5)